Related references
Note: Only part of the references are listed.Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes
Jingyi Lu et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
Role of Composite Glycemic Indices: A Comparison of the Comprehensive Glucose Pentagon Across Diabetes Types and HbA1c Levels
Suresh Rama Chandran et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
Differences for Percentage Times in Glycemic Range Between Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring in Adults with Type 1 Diabetes: Analysis of the REPLACE-BG Dataset
Parizad Avari et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease
Laura Mayeda et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Connecting the Dots: Validation of Time in Range Metrics With Microvascular Outcomes
Irl B. Hirsch et al.
DIABETES CARE (2019)
Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies
Karl Kristensen et al.
DIABETOLOGIA (2019)
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Tadej Battelino et al.
DIABETES CARE (2019)
Associations between HbA1c and continuous glucose monitoring-derived glycaemic variables
I. B. Hirsch et al.
DIABETIC MEDICINE (2019)
Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters
Helen R. Murphy
DIABETOLOGIA (2019)
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Roy W. Beck et al.
DIABETES CARE (2019)
Comment on Bergenstal et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care 2018;41:2275-2280
Kristen M. Pluchino et al.
DIABETES CARE (2019)
The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes
Robert A. Vigersky et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2019)
Translating glycated hemoglobin A1c into time spent in glucose target range: A multicenter study
Jonathan Petersson et al.
PEDIATRIC DIABETES (2019)
Metrics to Evaluate Quality of Glycemic Control: Comparison of Time in Target, Hypoglycemic, and Hyperglycemic Ranges with Risk Indices
David Rodbard
DIABETES TECHNOLOGY & THERAPEUTICS (2018)
Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes
Jingyi Lu et al.
DIABETES CARE (2018)
Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring
Richard M. Bergenstal et al.
DIABETES CARE (2018)
Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Stephanie A. Amiel et al.
DIABETES CARE (2017)
Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial
Denice S. Feig et al.
LANCET (2017)
Maturation of CGM and Glycemic Measurements Beyond HbA1c-A Turning Point in Research and Clinical Decisions
Matthew C. Riddle et al.
DIABETES CARE (2017)
Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange
Gina Agiostratidou et al.
DIABETES CARE (2017)
International Consensus on Use of Continuous Glucose Monitoring
Thomas Danne et al.
DIABETES CARE (2017)
Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations: A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group
John R. Petrie et al.
DIABETES CARE (2017)
Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters
Lorena Alarcon-Casas Wright et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2017)
Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes
David Rodbard
DIABETES TECHNOLOGY & THERAPEUTICS (2017)
Measures of Glycemic Variability in Type 1 Diabetes and the Effect of Real-Time Continuous Glucose Monitoring
Ahmed H. El-Laboudi et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2016)
Q-Score: development of a new metric for continuous glucose monitoring that enables stratification of antihyperglycaemic therapies
Petra Augstein et al.
BMC ENDOCRINE DISORDERS (2015)
Association of time in blood glucose range with outcomes following cardiac surgery
Amr S. Omar et al.
BMC ANESTHESIOLOGY (2015)
Time in blood glucose range 70 to 140 mg/dl >80% is strongly associated with increased survival in non-diabetic critically ill adults
James S. Krinsley et al.
CRITICAL CARE (2015)
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
David M. Nathan
DIABETES CARE (2014)
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Steven J. Russell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients With Type 2 Diabetes
Robert A. Vigersky et al.
DIABETES CARE (2012)
Effect of Short-Term iPRO Continuous Glucose Monitoring on Hemoglobin A1c Levels in Clinical Practice
Gary M. Pepper et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2012)
Real-time continuous glucose monitoring system for treatment of diabetes: a systematic review
L. B. E. A. Hoeks et al.
DIABETIC MEDICINE (2011)
Translating the A1C assay into estimated average glucose values
David M. Nathan et al.
DIABETES CARE (2008)
Share Paper
